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LETTERS TO THE EDITOR
Randomized controlled trials on the comparative effect of treatment modalities
of central sleep apnea with Cheyne–Stokes Respiration on cardiovascular
outcomes and physiology studies required
Response toHunasikatti M. Effect of treatment of central sleep apnea/Cheyne-StokesRespiration on left ventricular ejection fraction in
heart failure: a network meta-analysis is not the answer. J Clin Sleep Med. 2020;16(4):651–652. doi:10.5664/jcsm.8304
Esther I. Schwarz, MD1,2; Malcolm Kohler, MD1,2
1Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland; 2Centre of Competence Sleep & Health Zurich, University of Zurich,
Zurich, Switzerland
We thank Dr. Hunasikatti for his interest in our recently pub-
lished network meta-analysis on the effects of established
treatment modalities for central sleep apnea with Cheyne–
Stokes Respiration (CSA/CSR) in heart failure—continuous
positive airway pressure (CPAP), adaptive servo-ventilation
(ASV), andnocturnal oxygen—on cardiac function.1,2Weagree
that this meta-analysis on cardiac function does not provide an
answer to the important question whether and how treating
CSA/CSR affects cardiovascular mortality. However, because
an impaired cardiac function is the hallmark of heart failure,
treatment effects on this outcome are of interest. Small ran-
domized controlled trials, especially on the comparative ef-
fectiveness of CPAP and ASV in patients with heart failure and
CSA/CSR, have provided contradictory findings. Pooling data
from comparable randomized controlled trials helps to estimate
treatment effects more precisely and thus come to a more reliable
conclusion. In addition, the network approach allows to combine
evidence from both direct comparisons of interventions within
randomized controlled trials and indirect comparisons across trials
based on a common comparator, which is an important aspect
because several small studies on 3 different treatment approaches
for CSA/CSR (comparing these to an inactive control or to each
other) are being used. Therefore, this network meta-analysis
currently provides the best evidence on the effects of nocturnal
positive pressure ventilation and oxygen supplementation on
cardiac function in patients with heart failure and CSA/CSR. In
addition, the aim was to analyze the role of patient characteristics
(although only possible on a study level), eg, severity of heart
failure or CSA/CSR on the treatment effect on cardiac function, to
better understand which patient types should be studied in future
randomized controlled trials. The analysis led to the conclusion
that both CPAP and ASV result in an improvement of left ven-
tricular ejection fraction (LVEF) of about 5%,which is close to the
minimum important difference and echocardiographic measure-
ment accuracy in LVEF. The effect size has been discussed in the
context of measurement accuracy, minimum important differ-
ence, and, in comparison to heart failure treatment with drugs.
In addition, we concluded that there are not enough data from
randomized controlled trials using supplemental oxygen in these
patients. The meta-analysis also demonstrated that within the
spectrumof systolic heart failure, the beneficial treatment effect on
LVEF was larger in more severe systolic heart failure.1
In agreement with Dr Hunasikatti,2 we discussed that there
are several unanswered questions in regard to treatment indi-
cations and modalities in patients with CSA/CSR. The un-
derlying mechanisms of the observed increased cardiovascular
mortality in the ASV arm of the SERVE-HF trial3 (Treatment of
Sleep-Disordered Breathing with Predominant Central Sleep
Apnea by Adaptive Servo Ventilation in Patients with Heart
Failure) are still not understood. Therefore, ongoing randomized
controlled trials like the Effect of Adaptive Servo-Ventilation on
Survival andCardiovascularHospital Admissions in Patients with
Heart Failure and Sleep Apnea (ADVENT) trial4 and new trials
in both patients with CSA/CSR and heart failure with pre-
served and with reduced ejection fraction are needed to provide
evidence to guide clinical practice. In addition, there is also a need
for physiological studies on the effect of positive pressure ven-
tilation on hemodynamics in heart failure. These aspects and
current limitations of our understanding of the role of CSA/CSR
and its treatment are discussed in the network meta-analysis.1
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